PortalPublikationenPrognostic information of glycogen phosphorylase isoenzyme B...

Prognostic information of glycogen phosphorylase isoenzyme BB in patients with suspected acute coronary syndrome

Standard

Prognostic information of glycogen phosphorylase isoenzyme BB in patients with suspected acute coronary syndrome. / Lillpopp, Lars; Tzikas, Stergios; Ojeda, Francisco; Zeller, Tanja; Baldus, Stephan; Bickel, Christoph; Sinning, Christoph R; Wild, Philipp S; Genth-Zotz, Sabine; Warnholtz, Ascan; Lackner, Karl J; Münzel, Thomas; Blankenberg, Stefan; Keller, Till.

in: AM J CARDIOL, Jahrgang 110, Nr. 9, 01.11.2012, S. 1225-1230.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Lillpopp, L, Tzikas, S, Ojeda, F, Zeller, T, Baldus, S, Bickel, C, Sinning, CR, Wild, PS, Genth-Zotz, S, Warnholtz, A, Lackner, KJ, Münzel, T, Blankenberg, S & Keller, T 2012, 'Prognostic information of glycogen phosphorylase isoenzyme BB in patients with suspected acute coronary syndrome', AM J CARDIOL, Jg. 110, Nr. 9, S. 1225-1230. https://doi.org/10.1016/j.amjcard.2012.06.020

APA

Lillpopp, L., Tzikas, S., Ojeda, F., Zeller, T., Baldus, S., Bickel, C., Sinning, C. R., Wild, P. S., Genth-Zotz, S., Warnholtz, A., Lackner, K. J., Münzel, T., Blankenberg, S., & Keller, T. (2012). Prognostic information of glycogen phosphorylase isoenzyme BB in patients with suspected acute coronary syndrome. AM J CARDIOL, 110(9), 1225-1230. https://doi.org/10.1016/j.amjcard.2012.06.020

Vancouver

Lillpopp L, Tzikas S, Ojeda F, Zeller T, Baldus S, Bickel C et al. Prognostic information of glycogen phosphorylase isoenzyme BB in patients with suspected acute coronary syndrome. AM J CARDIOL. 2012 Nov 1;110(9):1225-1230. https://doi.org/10.1016/j.amjcard.2012.06.020

Bibtex

@article{620e131168cf40268939989eb43d0210,
title = "Prognostic information of glycogen phosphorylase isoenzyme BB in patients with suspected acute coronary syndrome",
abstract = "Early and adequate risk stratification is essential in patients with suspected acute coronary syndrome (ACS). The aim of the present study was to investigate whether glycogen phosphorylase BB (GPBB) could add prognostic information in the context of contemporary sensitive troponin I determination and B-type natriuretic peptide (BNP). Patients with suspected ACS were consecutively enrolled at 3 German study centers from January 2007 through December 2008. Troponin I, GPBB, and BNP were determined at admission. Follow-up information on the combined end point of death, myocardial infarction, revascularization, and hospitalization owing to a cardiovascular cause was obtained 6 months after enrollment. In total 1,818 patients (66% men) were enrolled of whom 413 (23%) were diagnosed as having acute myocardial infarction and 240 (13%) as having unstable angina pectoris, whereas in 1,165 patients (64%) an ACS could be excluded. Follow-up information was available in 98% of patients; 203 events were registered. GPBB measured on admission predicted an unfavorable outcome with a hazard ratio of 1.24 (p <0.05) in an unadjusted Cox regression model and showed a tendency with a hazard ratio of 1.13 (p = 0.07) in a fully adjusted model. Kaplan-Meier analysis revealed a poorer outcome in patients with increased GPBB levels amendatory to the information provided by troponin I or BNP. In conclusion, GPBB measurement provides predictive information on midterm prognosis in patients with chest pain in addition to BNP and troponin I.",
keywords = "Acute Coronary Syndrome/blood, Aged, Angina, Unstable/blood, Biomarkers/blood, Case-Control Studies, Chest Pain/blood, Cohort Studies, Female, Glycogen Phosphorylase, Brain Form/blood, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction/blood, Natriuretic Peptide, Brain/blood, Predictive Value of Tests, Prognosis, Risk Assessment, Sensitivity and Specificity, Severity of Illness Index, Survival Analysis, Troponin T/blood",
author = "Lars Lillpopp and Stergios Tzikas and Francisco Ojeda and Tanja Zeller and Stephan Baldus and Christoph Bickel and Sinning, {Christoph R} and Wild, {Philipp S} and Sabine Genth-Zotz and Ascan Warnholtz and Lackner, {Karl J} and Thomas M{\"u}nzel and Stefan Blankenberg and Till Keller",
note = "Copyright {\textcopyright} 2012 Elsevier Inc. All rights reserved.",
year = "2012",
month = nov,
day = "1",
doi = "10.1016/j.amjcard.2012.06.020",
language = "English",
volume = "110",
pages = "1225--1230",
journal = "AM J CARDIOL",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

RIS

TY - JOUR

T1 - Prognostic information of glycogen phosphorylase isoenzyme BB in patients with suspected acute coronary syndrome

AU - Lillpopp, Lars

AU - Tzikas, Stergios

AU - Ojeda, Francisco

AU - Zeller, Tanja

AU - Baldus, Stephan

AU - Bickel, Christoph

AU - Sinning, Christoph R

AU - Wild, Philipp S

AU - Genth-Zotz, Sabine

AU - Warnholtz, Ascan

AU - Lackner, Karl J

AU - Münzel, Thomas

AU - Blankenberg, Stefan

AU - Keller, Till

N1 - Copyright © 2012 Elsevier Inc. All rights reserved.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Early and adequate risk stratification is essential in patients with suspected acute coronary syndrome (ACS). The aim of the present study was to investigate whether glycogen phosphorylase BB (GPBB) could add prognostic information in the context of contemporary sensitive troponin I determination and B-type natriuretic peptide (BNP). Patients with suspected ACS were consecutively enrolled at 3 German study centers from January 2007 through December 2008. Troponin I, GPBB, and BNP were determined at admission. Follow-up information on the combined end point of death, myocardial infarction, revascularization, and hospitalization owing to a cardiovascular cause was obtained 6 months after enrollment. In total 1,818 patients (66% men) were enrolled of whom 413 (23%) were diagnosed as having acute myocardial infarction and 240 (13%) as having unstable angina pectoris, whereas in 1,165 patients (64%) an ACS could be excluded. Follow-up information was available in 98% of patients; 203 events were registered. GPBB measured on admission predicted an unfavorable outcome with a hazard ratio of 1.24 (p <0.05) in an unadjusted Cox regression model and showed a tendency with a hazard ratio of 1.13 (p = 0.07) in a fully adjusted model. Kaplan-Meier analysis revealed a poorer outcome in patients with increased GPBB levels amendatory to the information provided by troponin I or BNP. In conclusion, GPBB measurement provides predictive information on midterm prognosis in patients with chest pain in addition to BNP and troponin I.

AB - Early and adequate risk stratification is essential in patients with suspected acute coronary syndrome (ACS). The aim of the present study was to investigate whether glycogen phosphorylase BB (GPBB) could add prognostic information in the context of contemporary sensitive troponin I determination and B-type natriuretic peptide (BNP). Patients with suspected ACS were consecutively enrolled at 3 German study centers from January 2007 through December 2008. Troponin I, GPBB, and BNP were determined at admission. Follow-up information on the combined end point of death, myocardial infarction, revascularization, and hospitalization owing to a cardiovascular cause was obtained 6 months after enrollment. In total 1,818 patients (66% men) were enrolled of whom 413 (23%) were diagnosed as having acute myocardial infarction and 240 (13%) as having unstable angina pectoris, whereas in 1,165 patients (64%) an ACS could be excluded. Follow-up information was available in 98% of patients; 203 events were registered. GPBB measured on admission predicted an unfavorable outcome with a hazard ratio of 1.24 (p <0.05) in an unadjusted Cox regression model and showed a tendency with a hazard ratio of 1.13 (p = 0.07) in a fully adjusted model. Kaplan-Meier analysis revealed a poorer outcome in patients with increased GPBB levels amendatory to the information provided by troponin I or BNP. In conclusion, GPBB measurement provides predictive information on midterm prognosis in patients with chest pain in addition to BNP and troponin I.

KW - Acute Coronary Syndrome/blood

KW - Aged

KW - Angina, Unstable/blood

KW - Biomarkers/blood

KW - Case-Control Studies

KW - Chest Pain/blood

KW - Cohort Studies

KW - Female

KW - Glycogen Phosphorylase, Brain Form/blood

KW - Humans

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Myocardial Infarction/blood

KW - Natriuretic Peptide, Brain/blood

KW - Predictive Value of Tests

KW - Prognosis

KW - Risk Assessment

KW - Sensitivity and Specificity

KW - Severity of Illness Index

KW - Survival Analysis

KW - Troponin T/blood

U2 - 10.1016/j.amjcard.2012.06.020

DO - 10.1016/j.amjcard.2012.06.020

M3 - SCORING: Journal article

C2 - 22818785

VL - 110

SP - 1225

EP - 1230

JO - AM J CARDIOL

JF - AM J CARDIOL

SN - 0002-9149

IS - 9

ER -